RxDoctor Payments Data

Matthew Kronick, MD

Vascular Surgery · Springfield, MANPI 1619233699

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,337 of the $6,314 with a category attached, or 68.7%. 12 manufacturers reported payments, led by Cook Medical LLC at 26.6% of the total. Reporting peaked in 2019 at $2,280 and has fallen 82.0% since, to $409 in 2025.

$6,314in general payments, 2019–2025

Across 72 payments — averaging $87.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$2K
  • Silk Road Medical, Inc.$1K
  • Bolton Medical Inc$817
  • Endologix LLC$572
  • Abbott$545
  • W. L. Gore & Associates, Inc.$401
  • plus $968 from 6 others
$61,676in research payments, 2019–2025

Across 12 payments — averaging $5139.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$62K

What the payments were for

  • Speaking & faculty fees$5008%
  • Grants$67611%
  • Travel & lodging$80113%
  • Food & beverage$4,33769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,314 in reported general payments places this provider in the 60th percentile of 142 vascular surgery providers in Massachusetts.

See all vascular surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$209,366
Medicare patients
964
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$31,518
XareltoRivaroxaban29$24,029
ClopidogrelClopidogrel Bisulfate78$1,268
Cilostazol63$1,136
Atorvastatin Calcium48$711
Gabapentin36$576
Oxycodone Hcl26$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$31,51838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 142 vascular surgery providers in Massachusetts.

Other vascular surgery in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →